Lantern Pharma (NASDAQ: LTRN), a clinical-stage precision oncology company that leverages artificial intelligence and machine learning to develop cancer therapies, has scheduled a webcast to discuss its second-quarter 2026 operating and financial results. The event is set for Aug. 14, 2026, at 9 a.m. ET, and will be led by President and CEO Panna Sharma, along with other members of the management team.
The webcast will cover financial results for the quarter ended June 30, 2026, and provide updates on upcoming milestones, clinical trials, and developments involving the company’s proprietary RADR® platform and its Open-Medicine AI platforms. A replay will be available on the investor relations section of Lantern Pharma’s website following the event. The full press release can be accessed at https://ibn.fm/l80kv.
Lantern Pharma is known for its RADR® platform, which uses AI and machine learning to transform the development of cancer therapies. The company’s clinical pipeline includes several promising drug candidates: LP-184, an acylfulvene derivative targeting multiple solid tumors; LP-284, a TC-NER targeting compound for hematologic and solid tumors; and LP-300, a cisplatin/ethacraplatin analog that is being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. Additionally, LP-184 is being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
A significant development for Lantern is the commercial launch of withZeta.ai, a multi-agentic AI co-scientist platform now available as a subscription-based research platform for the global biomedical and drug development community. This launch represents a new revenue stream for the company, signaling a strategic expansion beyond its clinical pipeline into AI-driven research tools. The company also operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas.
The upcoming webcast is important for investors and industry observers because it will provide insights into Lantern’s financial health and the progress of its clinical programs. With the commercial availability of withZeta.ai, the company is positioning itself to generate recurring revenue, which could reduce its reliance on external funding. This move also highlights the broader trend of AI integration in drug discovery and development, where companies are leveraging computational platforms to accelerate timelines and reduce costs.
Lantern’s focus on AI-driven oncology is particularly relevant as the industry faces increasing pressure to improve efficiency and success rates in drug development. By combining its RADR® platform with the newly launched withZeta.ai, Lantern aims to offer a comprehensive suite of tools that could benefit not only its own pipeline but also external researchers and biopharma companies. The webcast will likely elaborate on how these platforms are being adopted and what milestones are expected in the coming quarters.
For more information about Lantern Pharma, visit the company’s newsroom at https://ibn.fm/LTRN.
